Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally, has entered into a strategic partnership with US medical technology giant Becton, Dickinson and Co. (BD). The collaboration focuses on the single cell instrument HT Xpress and the establishment of a joint laboratory dedicated to single cell multi-omics research. While the financial details of the agreement were not disclosed, the partnership signifies a significant step forward in advancing single cell sequencing technologies.
Single cell sequencing technology represents a groundbreaking advancement in life sciences, offering the ability to explore cellular diversity and heterogeneity at an unprecedented level. This cutting-edge technique enables researchers to conduct in-depth studies into the complex temporal and spatial relationships between cells, paving the way for new discoveries and innovations in the field.- Flcube.com
